Trials / Withdrawn
WithdrawnNCT00830882
Peak Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol
A Proof of Concept Study to Evaluate the Peak Bronchoprotection Conferred by Single and Chronic Dosing With Levosalbutamol and Racemic Salbutamol in Persistent Asthmatics.
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Dundee · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to compare the peak dose relative bronchoprotection offered by levosalbutamol and racemic salbutamol in mild to moderate asthmatics preselected into two groups on the basis of their beta-2 adrenoreceptor polymorphisms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | levosalbutamol | 2 puffs four times a day for 2 weeks |
| DRUG | racemic salbutamol | 2 puffs four times a day for 2 weeks |
| DRUG | placebo | 2 puffs four times a day for 2 weeks |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2010-01-01
- Completion
- 2010-01-01
- First posted
- 2009-01-28
- Last updated
- 2012-06-12
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00830882. Inclusion in this directory is not an endorsement.